HighLight Capital Joins $10M Round In Chinese Innovative Drug Developer Ennovabio

September 13, 2017 — 12:17 CST

This Data Is Locked!

This area is available only to Subscribers.

Chinese innovative drug developer Ennovabio has raised a US$10 million pre-A round from healthcare-focused venture capital firm HighLight Capital, a firm founded by former CDH... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Related Data:

Saudi Arabia’s FoFs Jada Backs eWTP Arabia Capital’s Second Fund

December 9, 2023 — 02:30

Chinese Charitable Foundations Expand Into Alternative Investments To Enhance Returns

November 30, 2023 — 23:50

Chinese Generative AI Startups Secure Substantial Funding in Race to Replicate OpenAI’s Success

November 13, 2023 — 23:55

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

Reports Indicate NVIDIA Tailoring Specialized Chips for China’s Market

November 9, 2023 — 23:26

Kai-Fu Lee’s AI Firm 01.AI Hits Unicorn Status with Alibaba Cloud-Led Funding

November 7, 2023 — 00:55

AI-Driven Pharmaceutical Startups Attract Soaring Investor Interest

November 5, 2023 — 03:24

ByteDance Invested In 52 Deals With Total Deal Value Of $6.4B: TikTok Parent Company’s Investments, M&A, Strategic Deals In One Chart 2019-2022

April 29, 2022 — 01:44

China’s Venture Mega-Deals 2019 to 2022 In One Chart: Can It Last?

April 15, 2022 — 00:30